Key Insights• The United Kingdom radiotherapy market operates within a predominantly public healthcare system, with the National Health Service serving as the primary purchaser and provider of radiation oncology services. Cancer remains a leading cause of mortality in the UK, with radiotherapy playing a central role in curative and palliative treatment for approximately 40–50% of all cancer patients.• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, reflecting the widespread installed base of linear accelerators across NHS trusts. Major international manufacturers including Varian Medical Systems, Elekta, and Accuray dominate the equipment supply market through NHS Supply Chain framework agreements .• Radiotherapy systems and equipment represent the largest offering segment, with the market characterized by centralized government funding for equipment replacement. NHS England has provided centralised funding for hospitals in need of replacement systems, with NHS Supply Chain procuring 28 new linear accelerators in 2025/2026, delivering £21.8 million in savings to the NHS .• Hospitals and integrated cancer centres are the largest end-user segment, operating within the NHS trust structure. Independent radiotherapy centres represent a smaller but growing segment, providing services outside the public framework. The University Hospitals of Leicester NHS Trust partnership with Ergéa exemplifies the managed equipment services model for radiotherapy fleet modernization .• Regulatory oversight is provided by the Care Quality Commission under the Ionising Radiation (Medical Exposure) Regulations 2017, with dedicated inspection programmes for radiotherapy services.

Amendments to IR(ME)R effective October 2024 introduced new requirements for collaborative working and establishment of dose reference levels in radiotherapy practice .Market Outlook• According to the research report, "United Kingdom Radiotherapy Market Overview, 2031 Outlook," published by Actual Market Research, the UK Radiotherapy market is anticipated to add more than USD 160 Million by 2026–31. This growth trajectory reflects sustained NHS investment in radiotherapy infrastructure, technology modernization, and increasing cancer burden across the aging population.• The market is expected to benefit from continued government investment in radiotherapy equipment. NHS Supply Chain has procured 28 new linear accelerator systems in 2025/2026 through its framework agreement from three suppliers Varian Medical Systems UK Ltd, Elekta Ltd, and Accuray UK Ltd with centralised government funding provided by NHS England . This procurement activity demonstrates sustained public sector commitment to equipment renewal.• Technology adoption is accelerating across NHS trusts. The University Hospitals of Leicester NHS Trust, in partnership with managed equipment services provider Ergéa, has modernised its entire radiotherapy fleet, upgrading four Varian TrueBeam linear accelerators and installing a state-of-the-art Halcyon system making UHL one of only ten UK centres equipped with this advanced accelerator . The upgrade delivered a 25% increase in treatment capacity.• The market is influenced by the managed equipment services model, where private providers partner with NHS trusts to provide capital investment, access to state-of-the-art equipment, and lifecycle optimisation. Ergéa UK has partnered with University Hospitals of Leicester since 2002, demonstrating the long-term viability of such arrangements .• Long-term growth is supported by demographic trends and sustained public funding.

The NHS continues to prioritise cancer care, with radiotherapy equipment replacement programmes aimed at reducing waiting times, enhancing treatment precision, and improving patient outcomes across the UK.Market DynamicsDriver: Sustained NHS Investment and Centralised ProcurementThe primary driver of the UK radiotherapy market is sustained public investment through the National Health Service and centralised procurement mechanisms. NHS Supply Chain, the organisation responsible for sourcing and delivering healthcare products to NHS trusts across England and Wales, manages framework agreements for radiotherapy equipment procurement . In 2025/2026, NHS Supply Chain procured 28 new linear accelerator systems for NHS cancer centres, backed by centralised government funding from NHS England. This procurement delivered £21.8 million in savings to the NHS while ensuring trusts access to cutting-edge technology. The modern technology reduces delays to treatment and, in some cases, reduces the number of hospital visits a patient needs by half, helping to cut waiting lists faster . This sustained investment cycle ensures consistent demand for equipment, installation services, and ongoing maintenance contracts.Challenge: Access Disparities and Workforce ConstraintsA significant challenge facing the UK radiotherapy market is geographic variation in access and equipment availability.

While major urban centres and large teaching hospitals benefit from advanced equipment fleets University Hospitals of Leicester NHS Trust operates four Varian TrueBeam and two Varian Halcyon linear accelerators access remains a challenge, especially in remote regions where disparities in healthcare infrastructure can limit the availability of advanced radiotherapy options . Additionally, the radiotherapy workforce faces recruitment and retention challenges, with clinical oncologists, medical physicists, and therapeutic radiographers in chronic shortage across the NHS. The complexity of modern equipment, including AI-driven adaptive systems and integrated imaging platforms, requires continuous training and professional development, adding to operational pressures.Trend: Managed Equipment Services and Lifecycle OptimisationA major trend shaping the UK radiotherapy market is the adoption of managed equipment services models, where private providers partner with NHS trusts to deliver comprehensive equipment management solutions. Ergéa UK has partnered with University Hospitals of Leicester NHS Trust since 2002, providing capital investment, access to state-of-the-art equipment, and lifecycle optimisation through a managed services approach . Under this model, the trust modernised its entire radiotherapy fleet, upgrading all linear accelerators and installing a Halcyon system within just four months. The partnership delivered a 25% increase in treatment capacity, improved treatment precision, and reduced waiting times .

This trend reflects broader NHS strategies to leverage private sector expertise and capital investment to modernise infrastructure while managing budget constraints, creating sustained demand for comprehensive service agreements.Policies• The Care Quality Commission regulates radiotherapy providers under the Ionising Radiation (Medical Exposure) Regulations 2017. CQC has a dedicated inspection programme for radiotherapy, assessing compliance with IR(ME)R regulations across both NHS and independent healthcare providers. Inspection teams include state-registered radiographers or clinical scientists with medical physics experience .• The Ionising Radiation (Medical Exposure) Regulations 2017 were amended effective October 2024. Key changes include a new Regulation 6A requiring cooperation between employers sharing involvement in patient exposure, and amendments to Regulation 12 establishing dose reference levels in radiotherapy practice and accommodating national differences in mental capacity and consent laws across England, Wales, and Scotland .• The Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 provides the overarching regulatory framework for healthcare providers. The CQC can take enforcement action where providers fail to meet requirements under this legislation .• NHS Supply Chain manages framework agreements for radiotherapy equipment procurement. In 2025/2026, NHS Supply Chain procured 28 new linear accelerator systems through its Imaging Radiotherapy Endoscopy Ancillary Devices and Related Goods and Services framework, achieving £21.8 million in savings for the NHS .• NHS England provides centralised government funding for radiotherapy LINAC replacement programmes.

This funding is distributed to NHS hospitals in need of replacement systems, ensuring equitable access to modern equipment across the country .• The Ionising Radiation Regulations 2017 establish requirements for radiation safety, personnel training, equipment testing, and incident reporting in facilities using ionising radiation, including radiotherapy departments.• The Medicines and Healthcare products Regulatory Agency regulates medical devices, including radiotherapy equipment, ensuring compliance with safety and performance standards. Equipment must meet regulatory requirements before being placed on the UK market.Segment AnalysisUK Radiotherapy Market By Therapy Type• External Beam Radiotherapy (EBRT): This is the largest therapy segment, reflecting the widespread installed base of linear accelerators across NHS trusts. The installed base includes conventional C-arm LINACs from Varian Medical Systems (TrueBeam, Halcyon) and Elekta, as well as specialised systems. The University Hospitals of Leicester NHS Trust operates four Varian TrueBeam and two Varian Halcyon linear accelerators . The segment is driven by the clinical dominance of IMRT, VMAT, IGRT, and SBRT techniques.• Internal / Brachytherapy: This segment is well-established in UK radiation oncology, particularly for prostate, gynaecological, breast, and head and neck cancers. Brachytherapy services are concentrated in specialised cancer centres and large NHS trusts with dedicated physics support and regulatory compliance infrastructure.• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies.

The regulatory framework under IR(ME)R provides specific provisions for administration of radioactive substances for treatment or diagnosis, accommodating national differences in consent laws across England, Wales, and Scotland .UK Radiotherapy Market By Offering• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by the high capital cost of linear accelerators and sustained government investment in equipment replacement. NHS Supply Chain procured 28 new linear accelerator systems in 2025/2026, representing a significant capital investment . Major suppliers include Varian Medical Systems UK Ltd, Elekta Ltd, and Accuray UK Ltd. Systems procured include advanced platforms such as the Halcyon LINAC, with the University Hospitals of Leicester being one of only ten UK centres equipped with this model .• Software & Services: This is the fastest-growing segment, reflecting the increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems the University Hospitals of North Midlands NHS Trust operates Varian Eclipse version 18.0 for treatment planning and oncology information systems such as Varian Aria . The services component encompasses installation, comprehensive maintenance, clinical training, physics support, and technical support.

Managed equipment services providers, including Ergéa UK, deliver comprehensive lifecycle optimisation through long-term partnerships .UK Radiotherapy Market By Application• Breast Cancer: This is a major application segment, with breast cancer ranking among the most frequent malignancies in the UK. Radiotherapy plays a central role in breast-conserving therapy and post-mastectomy treatment. Hypofractionation protocols are widely adopted to optimise treatment efficiency.• Prostate Cancer: A significant application area, with widespread use of EBRT, SBRT, and brachytherapy. UK radiation oncology departments offer advanced prostate cancer treatment with image guidance and real-time tracking.• Lung Cancer: This segment is growing, with increased adoption of SBRT for early-stage and oligometastatic disease. The National Institute for Health and Care Excellence provides clinical guidance on lung cancer radiotherapy.• Head & Neck Cancer: This is a critical application due to anatomical complexity, requiring highly conformal radiation delivery. IMRT and VMAT are the standard of care, and this segment often leads adoption of advanced image-guided platforms.• Central Nervous System / Brain: This is the fastest-growing application, driven by stereotactic radiosurgery for brain metastases and advanced radiotherapy for primary CNS tumours.

The Clatterbridge Cancer Centre NHS Foundation Trust, which received a new LINAC through the 2025/2026 procurement programme, specialises in advanced CNS treatments .• Gastro-intestinal: Applications include oesophageal, rectal, liver, and pancreatic cancers. UK academic centres are active in clinical trials on radiochemotherapy for gastrointestinal malignancies.• Other Applications: Includes gynaecological, haematological, paediatric, and palliative care indications. The Royal Marsden NHS Foundation Trust, which received a new LINAC in the 2025/2026 programme, is a world-leading cancer centre providing comprehensive radiotherapy services across multiple applications .UK Radiotherapy Market By End User• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the NHS trust structure. The 2025/2026 NHS Supply Chain procurement delivered new LINACs to 28 NHS trusts across England and Wales, including The Christie NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, and University College London Hospitals NHS Foundation Trust . The Christie, which received a new state-of-the-art system, noted the upgrade marks a significant step forward in advanced radiotherapy delivery .• Standalone Radiotherapy Centres: This segment is growing as independent providers offer services outside the NHS framework. The CQC regulates both NHS and independent healthcare providers under IR(ME)R, with dedicated inspection programmes for radiotherapy services across both sectors .• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in advancing the field through clinical trials and technology validation.

Major academic centres including The Royal Marsden and The Christie are at the forefront of radiation oncology research, participating in national and international clinical trials.• Other Healthcare Facilities: This includes community hospitals and palliative care facilities, contributing to broad-based demand for radiotherapy services across the UK.UK Radiotherapy Market Economics• Service contract pricing and maintenance costs vary by equipment type and age. Managed equipment services providers such as Ergéa UK offer comprehensive lifecycle optimisation, including capital investment, access to state-of-the-art equipment, and ongoing maintenance . Long-term partnerships, such as the 20-year relationship between Ergéa and University Hospitals of Leicester, provide predictable maintenance costs and guaranteed uptime.• Equipment procurement in the UK is predominantly conducted through NHS Supply Chain framework agreements, which achieve significant cost savings through centralised purchasing. The 2025/2026 LINAC procurement delivered £21.8 million in savings for the NHS .• The NHS provides centralised government funding for radiotherapy equipment replacement programmes. This funding model ensures consistent investment cycles and reduces financial pressure on individual trusts .• The economic value of radiotherapy is well-recognised in the UK. The modern technology reduces delays to treatment and, in some cases, reduces the number of hospital visits a patient needs by half, contributing to healthcare system efficiency .• Equipment downtime directly affects patient access, treatment schedules, and clinical outcomes.

With NHS trusts operating complex equipment fleets the University Hospitals of North Midlands NHS Trust operates two Varian TrueBeam and two Varian Halcyon LINACs effective maintenance programmes are critical to ensure uninterrupted access to radiotherapy services .• The cost of cybersecurity maintenance is an emerging economic factor, requiring budget allocation for software patch management and vulnerability remediation across connected radiotherapy device fleets.Market Outlook by Infrastructure, Investment and Industry Development• NHS England has provided centralised government funding for radiotherapy LINAC replacement programmes, enabling NHS trusts to replace aging equipment with state-of-the-art systems. NHS Supply Chain has procured 28 new linear accelerators in 2025/2026, delivering £21.8 million in savings to the NHS .• Investment in radiotherapy equipment spans 28 NHS trusts across England and Wales, including major cancer centres such as The Christie NHS Foundation Trust and The Royal Marsden NHS Foundation Trust. The modernised equipment enhances treatment precision, reduces waiting times, and supports the NHS's efforts to catch and treat more cancers faster .• The managed equipment services model is expanding, with private providers partnering with NHS trusts to deliver comprehensive equipment management solutions. Ergéa UK's partnership with University Hospitals of Leicester NHS Trust since 2002 demonstrates the long-term viability of such arrangements, providing capital investment and lifecycle optimisation .• Digital transformation is enabling remote diagnostics, predictive maintenance, and real-time performance monitoring of radiotherapy equipment. Treatment planning systems such as Varian Eclipse (version 18.0) and oncology information systems such as Varian Aria are increasingly deployed across NHS trusts .• Regulatory oversight through the CQC's dedicated radiotherapy inspection programme ensures high standards of safety and quality across both NHS and independent providers. IR(ME)R inspections assess compliance with regulations and may include recommendations to improve practice or specify actions required to achieve compliance .• The Ionising Radiation (Medical Exposure) Regulations 2017 amendments effective October 2024 introduced new requirements for collaborative working between employers and the establishment of dose reference levels in radiotherapy practice, reflecting the evolving regulatory landscape .• The long-term outlook remains positive as cancer incidence continues to rise, technology innovation accelerates, and the critical role of radiotherapy in comprehensive cancer care remains a cornerstone of the UK's healthcare system.

Sustained public investment through NHS procurement mechanisms and the managed equipment services model positions the UK radiotherapy market for continued growth through 2031.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Radiotherapy Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Therapy Type• External Beam Radiotherapy (EBRT)• Internal / Brachytherapy• Systemic RadiotherapyBy Offering• Radiotherapy Systems/Equipment• Software & ServicesBy Application• Breast Cancer• Prostate Cancer• Lung Cancer• Head & Neck Cancer• Central Nervous System / Brain• Gastro-intestinal• Other ApplicationsBy End User• Hospitals & Integrated Cancer Centers• Standalone Radiotherapy Centers• Academic/Research Institutions• Other Healthcare Facilities.